Curia Inc - Strategic SWOT Analysis Review

July 2021 | 36 pages | ID: A85B18E8C15EN
GlobalData

Abstracts

Curia Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Curia Inc (Curia), formerly Albany Molecular Research Inc, is a contract research development and manufacturing organization. Its service portfolio includes drug discovery and development, manufacturing of active pharmaceutical ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclinical, clinical and commercial projects; manufacture of drug product for new and generic drugs and project management services. The company serves pharmaceutical and biotechnology companies. Curia offers drug discovery and development services across various therapeutic areas, including infectious diseases, CNS, metabolic disorders, cardiovascular, and oncology, among others. It has presence in North America, Europe and Asia. Curia is headquartered in Albany, New York, the US.

Curia Inc Key Recent Developments

Jul 11,2021: AMRI becomes Curia
Apr 30,2021: AMRI adds to accelerated R&D and manufacturing solutions for orphan products to treat rare diseases
Feb 25,2021: AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine
Feb 08,2021: AMRI Appoints Scott Waldman to Lead Corporate Development
Jan 11,2021: AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Curia Inc - Key Facts
Curia Inc - Key Employees
Curia Inc - Key Employee Biographies
Curia Inc - Major Products and Services
Curia Inc - History
Curia Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Curia Inc - Business Description
Curia Inc - SWOT Analysis
SWOT Analysis - Overview
Curia Inc - Strengths
Curia Inc - Weaknesses
Curia Inc - Opportunities
Curia Inc - Threats
Curia Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Curia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Curia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Curia Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Apr 30, 2021: AMRI adds to accelerated R&D and manufacturing solutions for orphan products to treat rare diseases
Feb 25, 2021: AMRI Joins Network of Approved Manufacturers of Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine
Feb 08, 2021: AMRI Appoints Scott Waldman to Lead Corporate Development
Jan 11, 2021: AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1
Apr 30, 2020: AMRI increases hydroxychloroquine sulfate API production in U.S. to meet potential COVID-19 demand
Apr 23, 2020: AMRI leads the industry in highest ranking from SafeBridge for highly potent compound safety

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Curia Inc, Key Facts
Curia Inc, Key Employees
Curia Inc, Key Employee Biographies
Curia Inc, Major Products and Services
Curia Inc, History
Curia Inc, Other Locations
Curia Inc, Subsidiaries
Curia Inc, Key Competitors
Curia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Curia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Curia Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Curia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Curia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021